National Cancer Institute (NCI): Thymus Neoplasms trials

The registry lists 13 Thymus Neoplasms studies with National Cancer Institute (NCI) as lead sponsor. 2 are open to participants now and 7 have results posted.

Phase 1 4Phase 2 9No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including MesotheliomaRecruitingNCT06885697Phase 1
• PT-112 in Subjects With Thymoma and Thymic CarcinomaRecruitingNCT05104736Phase 2
• Continuous 24h Intravenous Infusion of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in People With Primary Thoracic Malignancies or Carcinomas, Sarcomas or Germ Cell Neoplasms With Pleuropulmonary MetastasesTerminatedNCT02859415Phase 1/2Results posted
• Cognitive Testing of Tobacco Use Measurement Items for Administration With Cancer Patients and SurvivorsCompletedNCT02233842Results posted
• Sunitinib for Advanced Thymus Cancer Following Earlier TreatmentCompletedNCT01621568Phase 2Results posted
• A Phase 1/2 Study of PXD101 (Belinostat) in Combination With Cisplatin, Doxorubicin and Cyclophosphamide in the First Line Treatment of Advanced or Recurrent Thymic, MalignanciesTerminatedNCT01100944Phase 1/2Results posted
• Multicenter Phase II Study of IMC-A12 in Patients With Thymoma and Thymic Carcinoma Who Have Been Previously Treated With ChemotherapyCompletedNCT00965250Phase 2Results posted
• Saracatinib in Treating Patients With Relapsed or Refractory Thymoma or Thymic CancerTerminatedNCT00718809Phase 2Results posted
• Belinostat (PXD101) to Treat Tumors of the Thymus at an Advanced StageCompletedNCT00589290Phase 2Results posted
• Bintrafusp Alfa (M7824) in Subjects With Thymoma and Thymic CarcinomaActive, not recruitingNCT04417660Phase 2
• Rapid Autopsy and Procurement of Cancer TissueTerminatedNCT01851395
• 18F FLT Imaging Studies of Treatment Response for Lung Cancer and ThymomaWithdrawnNCT01610544Phase 2
• Pilot Study of Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers, Thymic Neoplasms, and Malignant Pleural MesotheliomasTerminatedNCT01143545Phase 1